[A novel Cisplatin delivery system for malignant ascites-bearing mice-a basic experimentation]

Area of Science:

• Biomaterials Science
• Oncology
• Drug Delivery Systems

Context:

• Malignant ascites poses a significant therapeutic challenge.
• Conventional chemotherapy, like cisplatin (CDDP), has limitations in efficacy and side effects.
• Developing advanced drug delivery systems (DDS) is crucial for improving cancer treatment outcomes.

Purpose:

• To develop and evaluate a novel anticancer drug delivery system (DDS) based on 70% deacetylated chitin and cisplatin (CDDP).
• To assess the in vitro drug release profile of CDDP from the novel DDS.
• To investigate the in vivo efficacy and immunological mechanisms of the novel DDS in a mouse model of malignant ascites.

Summary:

• The novel DDS demonstrated sustained in vitro release of CDDP, with 70-90% delivered within 24 hours.
• Intraperitoneal administration of the DDS in mice with malignant ascites resulted in a 4-week survival rate of 19/30, with no ascites recurrence.
• Control groups showed significantly lower survival rates (5/14 for conventional CDDP) or rapid mortality (untreated mice).

Impact:

• The novel chitin-based DDS shows promise for clinical application in treating malignant ascites.
• The system effectively suppressed ascites progression and prolonged survival in a preclinical model.
• Immunological investigations indicated that the DDS induced a cytotoxic immunoresponse, suggesting a multifaceted therapeutic mechanism.